Loading...

Artelo Biosciences, Inc.

ARTL•NASDAQ
Healthcare
Biotechnology
$28.50
$6.90(31.94%)

Artelo Biosciences, Inc. (ARTL) Stock Overview

Explore Artelo Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap15.4M
P/E Ratio-1.29
EPS (TTM)$-17.94
ROE-0.64%
Fundamental Analysis

AI Price Forecasts

1 Week$1.18
1 Month$1.05
3 Months$0.53
1 Year Target$0.46

ARTL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Artelo Biosciences, Inc. (ARTL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 81.89, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.46.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.29 and a market capitalization of 15.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

81.89RSI (14)
3.47MACD
70.33ADX
Stats data is not available for ARTLStats details for ARTL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ARTLAnalyst Recommendations details for ARTL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

CEO

Gregory D. Gorgas

Employees

6

Headquarters

505 Lomas Santa Fe, Solana Beach, CA

Founded

2019

Frequently Asked Questions

;